Literature DB >> 35283324

Longitudinal Analysis of the Retina and Choroid in Cognitively Normal Individuals at Higher Genetic Risk of Alzheimer Disease.

Justin P Ma1, Cason B Robbins1, Jia Min Lee2, Srinath Soundararajan1, Sandra S Stinnett1, Rupesh Agrawal3, Brenda L Plassman4, Eleonora M Lad5, Heather Whitson5, Dilraj S Grewal1, Sharon Fekrat6.   

Abstract

PURPOSE: To assess the baseline differences and longitudinal rate of change in retinal and choroidal imaging parameters between apolipoprotein ε4 (APOE ε4) carriers and noncarriers with normal cognition.
DESIGN: Prospective study.
SUBJECTS: Four hundred thirteen eyes of 218 individuals with normal cognition aged ≥ 55 years with known APOE status (98 APOE ε4 carriers and 120 noncarriers). The exclusion criteria included diabetes mellitus, uncontrolled hypertension, glaucoma, and vitreoretinal or neurodegenerative disease.
METHODS: OCT and OCT angiography (OCTA) were performed at baseline and 2 years (Zeiss Cirrus HD-OCT 5000 with AngioPlex; Zeiss Meditec). The groups were compared using sex- and age-adjusted generalized estimating equations. MAIN OUTCOME MEASURES: OCT parameters: retinal nerve fiber layer thickness, macular ganglion cell-inner plexiform layer thickness, central subfield thickness (CST), and choroidal vascularity index. OCT angiography parameters: foveal avascular zone area, perfusion density (PD), vessel density, peripapillary capillary PD (CPD), and capillary flux index (CFI). The rate of change per year was calculated.
RESULTS: At the baseline, the APOE ε4 carriers had lower CST (P = 0.018), PD in the 6-mm ETDRS circle (P = 0.049), and temporal CFI (P = 0.047). Seventy-one APOE ε4 carriers and 78 noncarriers returned at 2 years; at follow-up, the 6-mm ETDRS circle (P = 0.05) and outer ring (P = 0.049) showed lower PD in the APOE ε4 carriers, with no differences in the rates of change between the groups (all P > 0.05).
CONCLUSIONS: There was exploratory evidence of differences in the CST, PD, and peripapillary CFI between the APOE ε4 carriers and noncarriers with normal cognition. Larger and longer-term studies may help further elucidate the potential prognostic value of these findings.
Copyright © 2022 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoliporroteinε4; Imaging; OCT; OCTA; Preclinical Alzheimer disease

Mesh:

Substances:

Year:  2022        PMID: 35283324      PMCID: PMC9271592          DOI: 10.1016/j.oret.2022.03.001

Source DB:  PubMed          Journal:  Ophthalmol Retina        ISSN: 2468-6530


  78 in total

Review 1.  Genotype and phenotype in Alzheimer's disease.

Authors:  Clive Holmes
Journal:  Br J Psychiatry       Date:  2002-02       Impact factor: 9.319

2.  Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.

Authors:  Ying Liu; Lan Tan; Hui-Fu Wang; Yong Liu; Xiao-Ke Hao; Chen-Chen Tan; Teng Jiang; Bing Liu; Dao-Qiang Zhang; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-08-23       Impact factor: 5.590

3.  Impaired Autophagy in APOE4 Astrocytes.

Authors:  Shira Simonovitch; Eran Schmukler; Alina Bespalko; Tal Iram; Dan Frenkel; David M Holtzman; Eliezer Masliah; Danny M Michaelson; Ronit Pinkas-Kramarski
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

4.  Spectral-Domain OCT Measurements in Alzheimer's Disease: A Systematic Review and Meta-analysis.

Authors:  Victor T T Chan; Zihan Sun; Shumin Tang; Li Jia Chen; Adrian Wong; Clement C Tham; Tien Y Wong; Christopher Chen; M Kamran Ikram; Heather E Whitson; Eleonora M Lad; Vincent C T Mok; Carol Y Cheung
Journal:  Ophthalmology       Date:  2018-08-13       Impact factor: 12.079

Review 5.  Apolipoprotein E in Alzheimer's disease: an update.

Authors:  Jin-Tai Yu; Lan Tan; John Hardy
Journal:  Annu Rev Neurosci       Date:  2014-04-21       Impact factor: 12.449

6.  Evaluation of inner retinal layers as biomarkers in mild cognitive impairment to moderate Alzheimer's disease.

Authors:  Eleonora M Lad; Dibyendu Mukherjee; Sandra S Stinnett; Scott W Cousins; Guy G Potter; James R Burke; Sina Farsiu; Heather E Whitson
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

7.  Synergistic interaction between APOE and family history of Alzheimer's disease on cerebral amyloid deposition and glucose metabolism.

Authors:  Dahyun Yi; Younghwa Lee; Min Soo Byun; Jun Ho Lee; Kang Ko; Bo Kyung Sohn; Young Min Choe; Hyo Jung Choi; Hyewon Baek; Chul-Ho Sohn; Yu Kyeong Kim; Dong Young Lee
Journal:  Alzheimers Res Ther       Date:  2018-08-23       Impact factor: 6.982

Review 8.  Alzheimer's disease: risk factors and potentially protective measures.

Authors:  Marcos Vinícius Ferreira Silva; Cristina de Mello Gomide Loures; Luan Carlos Vieira Alves; Leonardo Cruz de Souza; Karina Braga Gomes Borges; Maria das Graças Carvalho
Journal:  J Biomed Sci       Date:  2019-05-09       Impact factor: 8.410

9.  Decreased retinal thickness in patients with Alzheimer's disease is correlated with disease severity.

Authors:  Jae-Il Kim; Bong-Hui Kang
Journal:  PLoS One       Date:  2019-11-05       Impact factor: 3.240

10.  Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease.

Authors:  L Mosconi; B Nacmias; S Sorbi; M T R De Cristofaro; M Fayazz; A Tedde; L Bracco; K Herholz; A Pupi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

View more
  1 in total

1.  Retinal Vascular Study Using OCTA in Subjects at High Genetic Risk of Developing Alzheimer's Disease and Cardiovascular Risk Factors.

Authors:  Inés López-Cuenca; Elena Salobrar-García; Lidia Sánchez-Puebla; Eva Espejel; Lucía García Del Arco; Pilar Rojas; Lorena Elvira-Hurtado; José A Fernández-Albarral; Federico Ramírez-Toraño; Ana Barabash; Juan J Salazar; José M Ramírez; Rosa de Hoz; Ana I Ramírez
Journal:  J Clin Med       Date:  2022-06-06       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.